Nucleic acid therapeutics is a rapidly growing field in the pharmaceutical industry that utilizes nucleic acids, such as DNA, RNA, and synthetic analogs, to treat various diseases. These therapies work by modulating gene expression or silencing specific disease-causing genes. The development of advanced technologies like antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and gene editing tools like CRISPR-Cas9 has fueled the growth of this market. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established clear guidelines and accelerated pathways for the approval of nucleic acid therapeutics. This has encouraged pharmaceutical companies and biotechnology firms to invest in the development of these therapies. In recent years, several nucleic acid-based drugs have received regulatory approval, including Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis, Spinraza (nusinersen) for spinal muscular atrophy, and Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy. As more therapies demonstrate safety and efficacy in clinical trials, the number of regulatory approvals is expected to increase, driving market growth. The nucleic acid therapeutics market is on the cusp of a transformative era, with the potential to revolutionize the treatment of various diseases. As the technology continues to advance and more therapies reach the market, the future of this field looks promising.
According to the research report “Global Small Nucleic Acid Therapies Market Outlook , 2030," published by Bonafide Research, the Global Small Nucleic Acid Therapies Market is anticipated to grow at more than 3.9% CAGR from 2024 to 2030. One of the key challenges in nucleic acid therapeutics is the efficient delivery of these large, negatively charged molecules to the target cells or tissues. Researchers are actively working on developing innovative delivery systems that can protect the nucleic acids from degradation, facilitate cellular uptake, and ensure targeted delivery. These include lipid nanoparticles, polymeric carriers, cell-penetrating peptides, and exosome-based delivery systems. As these delivery technologies advance, the efficacy and safety of nucleic acid therapies are expected to improve. Nucleic acid therapeutics hold great promise in treating a wide range of diseases, including genetic disorders, cancer, viral infections, and chronic conditions. As our understanding of the human genome and disease pathways deepens, researchers are discovering new targets for these therapies. The ability to precisely target and modulate gene expression opens up new avenues for personalized medicine and the treatment of previously "undruggable" targets.
Market Dynamics
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Drivers
• Growing Demand for Targeted Therapies : One of the primary drivers of the nucleic acid therapeutics market is the increasing demand for targeted therapies that address the underlying genetic causes of diseases. Traditional treatments often focus on alleviating symptoms rather than addressing the root cause of diseases, which can lead to transient effects. Nucleic acid therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNAs (mRNAs), offer a novel approach by directly targeting genetic material to modify gene expression. This capability is particularly beneficial for genetic disorders, cancers, and viral infections, where conventional therapies may fall short. The success of recent nucleic acid-based drugs, such as Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis and Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy, highlights the potential of these therapies to provide long-lasting or curative effects. As more patients and healthcare providers recognize the benefits of these targeted approaches, the demand for nucleic acid therapeutics is expected to rise significantly.
• Regulatory Support and Approvals : Another significant driver influencing the nucleic acid therapeutics market is the increasing regulatory support and approvals from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The establishment of clear guidelines and accelerated pathways for the approval of nucleic acid-based therapies has fostered a favorable environment for research and development. Regulatory bodies are recognizing the potential of these therapies to address unmet medical needs, leading to a growing number of approvals for innovative treatments. The recent success of several nucleic acid therapeutics in clinical trials has encouraged pharmaceutical companies to invest in this area. As more therapies demonstrate safety and efficacy, the likelihood of regulatory approval increases, further motivating companies to develop new nucleic acid-based drugs. This trend is expected to continue, with regulatory agencies likely to maintain their supportive stance as they aim to expedite the availability of novel therapies to patients.
Market Challenges
• Delivery Challenges : Developing efficient delivery systems that can protect nucleic acids from degradation, facilitate cellular uptake, and ensure targeted delivery is critical for the success of these therapies. Various strategies have been explored, including the use of lipid nanoparticles, polymeric carriers, and viral vectors, but each method has its limitations. For instance, lipid nanoparticles have shown promise in delivering mRNA vaccines, but their use in other therapeutic applications may require further optimization. One of the most significant challenges facing the nucleic acid therapeutics market is the effective delivery of these molecules to target cells. Nucleic acids, such as DNA and RNA, are large, negatively charged molecules that are inherently difficult to deliver into cells. They are susceptible to degradation by nucleases in biological environments, which can significantly reduce their therapeutic efficacy.
• High Development Costs : The development of nucleic acid therapeutics is often associated with high costs, which can pose a significant barrier to market entry and accessibility. The complexity of designing, synthesizing, and testing nucleic acid-based therapies requires substantial investment in research and development. Additionally, the manufacturing processes for these therapies can be resource-intensive, requiring specialized facilities and equipment. The high costs associated with clinical trials further exacerbate this issue, as companies must navigate lengthy and expensive regulatory processes to bring their products to market. These financial barriers can deter smaller biotechnology firms from pursuing nucleic acid therapeutics, limiting innovation and competition in the market.
.Market Trends
• Advancements in Delivery Technologies : A significant trend shaping the nucleic acid therapeutics market is the ongoing advancements in delivery technologies. As the field matures, researchers are developing innovative delivery systems that enhance the stability, cellular uptake, and tissue specificity of nucleic acid therapies. Additionally, the development of targeted delivery systems, such as ligand-conjugated nanoparticles, is gaining traction. By attaching specific ligands to delivery vehicles, researchers can enhance the affinity of nucleic acids for target cells, improving the overall efficacy of the therapy. This trend towards more sophisticated delivery technologies is expected to expand the applications of nucleic acid therapeutics and overcome existing delivery challenges.
• Increased Focus on Personalized Medicine : Another notable trend in the nucleic acid therapeutics market is the increased focus on personalized medicine. As our understanding of genetic variations and their impact on disease progresses, there is a growing recognition of the need for tailored therapeutic approaches. Nucleic acid therapies, with their ability to target specific genes and pathways, are well-positioned to play a crucial role in this shift towards personalized treatment. Pharmaceutical companies are increasingly investing in research to develop nucleic acid-based therapies that can be customized to individual patients' genetic profiles. This approach not only enhances the likelihood of therapeutic success but also minimizes potential adverse effects by targeting the underlying causes of diseases rather than merely managing symptoms. The trend towards personalized medicine is expected to drive innovation in the nucleic acid therapeutics market, leading to the development of more effective and safer therapies.
End User
• Pharmaceutical Companies : Pharmaceutical companies are among the primary end users of nucleic acid therapeutics, driving research, development, and commercialization efforts in this field. These companies invest heavily in the development of innovative nucleic acid-based therapies to address unmet medical needs across a range of diseases, including genetic disorders, cancer, and infectious diseases. The increasing number of approved nucleic acid therapeutics has encouraged pharmaceutical companies to expand their portfolios and explore new therapeutic areas. The success of recent products, such as mRNA vaccines and gene therapies, has demonstrated the potential of nucleic acid technologies to revolutionize treatment paradigms. As a result, many pharmaceutical companies are actively pursuing collaborations and partnerships with biotechnology firms and academic institutions to leverage expertise and accelerate the development of nucleic acid therapeutics.
• Academic and Research Institutions : Academic and research institutions play a vital role as end users in the nucleic acid therapeutics market, contributing to the foundational research and development of these therapies. These institutions are at the forefront of scientific discovery, exploring novel approaches to gene modulation, delivery technologies, and therapeutic applications. Many breakthroughs in nucleic acid therapeutics have originated from academic research, leading to the development of innovative technologies and methodologies. Collaboration between academic institutions and industry partners is increasingly common, as pharmaceutical companies seek to leverage the expertise and resources available in academia. This partnership model fosters innovation and accelerates the translation of research findings into clinical applications.
Segmentation Analysis
Based on the report the product type is segmented into Antisense Oligonucleotides (ASO) , siRNA , mRNA
ASOs are short, synthetic strands of nucleic acids designed to bind to specific mRNA molecules, thereby modulating gene expression. They function primarily by preventing the translation of target mRNAs into proteins, which can be particularly useful in conditions where overexpression of a protein contributes to disease. ASOs have gained traction in treating genetic disorders, such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). For instance, Nusinersen (Spinraza), an ASO approved for SMA, has demonstrated significant clinical efficacy, leading to increased demand for similar therapies. siRNAs are short, double-stranded RNA molecules that play a crucial role in RNA interference (RNAi), a natural cellular mechanism for gene silencing. By binding to complementary mRNA sequences, siRNAs promote their degradation, effectively silencing the expression of specific genes. This mechanism has been harnessed therapeutically to target genes involved in various diseases, including genetic disorders, cancers, and viral infections. mRNA therapeutics have gained significant attention, especially in the wake of the COVID-19 pandemic, where mRNA vaccines demonstrated rapid development and efficacy. mRNAs serve as templates for protein synthesis, and by introducing synthetic mRNAs into the body, researchers can instruct cells to produce therapeutic proteins. This approach has implications for a wide range of diseases, including infectious diseases, cancer, and genetic disorders.
Based on the report the application is segmented into Neuromuscular Diseases , hATTR , COVID-19 , Other
Neuromuscular diseases, which include conditions like spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD), represent a significant application area for nucleic acid therapeutics. These diseases are primarily caused by genetic mutations that lead to the degeneration of motor neurons or muscle fibers. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) have been developed to target the underlying genetic causes of these disorders. For instance, Nusinersen (Spinraza), an ASO, has been approved for the treatment of SMA, demonstrating the ability to improve motor function and quality of life in affected patients. hATTR is a progressive and often fatal condition caused by the accumulation of misfolded transthyretin protein in various tissues, leading to neuropathy and cardiomyopathy. Recent advancements in nucleic acid therapeutics have led to the development of targeted therapies for hATTR, such as patisiran (Onpattro) and inotersen, which utilize RNA interference mechanisms to reduce the production of transthyretin. The COVID-19 pandemic has catalyzed the rapid development and deployment of nucleic acid-based therapeutics, particularly mRNA vaccines. The unprecedented global health crisis highlighted the need for swift and effective therapeutic solutions, leading to the approval of mRNA vaccines like those developed by Pfizer-BioNTech and Moderna. These vaccines utilize synthetic mRNA to instruct cells to produce a harmless piece of the virus's spike protein, prompting an immune response.
Regional Analysis
The Asia-Pacific (APAC) region is currently trending in the nucleic acid-based therapeutics market, primarily due to a combination of factors that enhance its growth potential.
This region is witnessing significant advancements in healthcare infrastructure, increased investments in research and development, and a growing demand for innovative therapies. Countries like China, India, and Japan are at the forefront of this transformation, driven by their vast populations, rising prevalence of chronic diseases, and a burgeoning biotechnology sector. Consumer preferences in the APAC region are shifting towards personalized medicine and advanced therapeutic options. There is an increasing awareness of genetic disorders and chronic diseases, leading to a greater demand for targeted therapies that can address the underlying genetic causes of these conditions. Patients and healthcare providers are increasingly looking for therapies that offer more effective and lasting solutions compared to traditional treatments. The APAC region presents numerous growth opportunities for nucleic acid therapeutics. Governments are increasingly investing in healthcare initiatives and biotechnology research, creating a supportive environment for innovation. For example, initiatives aimed at promoting medical tourism and enhancing healthcare access are likely to boost the demand for advanced therapeutic options, including nucleic acid-based treatments.
Key Development
• December 2016: The approval of Nusinersen (Spinraza), an antisense oligonucleotide for spinal muscular atrophy, marked a significant milestone in the application of nucleic acid therapeutics.
• June 2018: The FDA approved Patisiran (Onpattro), the first RNA interference therapy for hereditary transthyretin amyloidosis, showcasing the potential of siRNA in treating genetic disorders.
• December 2019: Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy, received approval, highlighting advancements in gene therapy approaches.
• December 2020: The emergency use authorization of mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna demonstrated the rapid development capabilities of nucleic acid-based therapies in response to global health crises.
• August 2021: The FDA's approval of Givosiran (Givlaari), a siRNA therapy for acute hepatic porphyria, further validated the therapeutic potential of RNA interference technologies.
Table of Contents
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Small Nucleic Acid Therapies Market Size 2019-2030
- 2.1.2 Small Nucleic Acid Therapies Market Size CAGR by Region (2019 VS 2023 VS 2030)
- 2.1.3 World Current & Future Analysis for Small Nucleic Acid Therapies by Country/Region, 2019, 2023 & 2030
- 2.2 Small Nucleic Acid Therapies Segment by Type
- 2.2.1 Antisense Oligonucleotides (ASO)
- 2.2.2 siRNA
- 2.2.3 mRNA
- 2.3 Small Nucleic Acid Therapies Market Size by Type
- 2.3.1 Small Nucleic Acid Therapies Market Size CAGR by Type (2019 VS 2023 VS 2030)
- 2.3.2 Global Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
- 2.4 Small Nucleic Acid Therapies Segment by Application
- 2.4.1 Neuromuscular Diseases
- 2.4.2 hATTR
- 2.4.3 COVID-19
- 2.4.4 Other
- 2.5 Small Nucleic Acid Therapies Market Size by Application
- 2.5.1 Small Nucleic Acid Therapies Market Size CAGR by Application (2019 VS 2023 VS 2030)
- 2.5.2 Global Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
- 3 Small Nucleic Acid Therapies Market Size by Player
- 3.1 Small Nucleic Acid Therapies Market Size Market Share by Player
- 3.1.1 Global Small Nucleic Acid Therapies Revenue by Player (2019-2024)
- 3.1.2 Global Small Nucleic Acid Therapies Revenue Market Share by Player (2019-2024)
- 3.2 Global Small Nucleic Acid Therapies Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Small Nucleic Acid Therapies by Region
- 4.1 Small Nucleic Acid Therapies Market Size by Region (2019-2024)
- 4.2 Global Small Nucleic Acid Therapies Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Small Nucleic Acid Therapies Market Size Growth (2019-2024)
- 4.4 APAC Small Nucleic Acid Therapies Market Size Growth (2019-2024)
- 4.5 Europe Small Nucleic Acid Therapies Market Size Growth (2019-2024)
- 4.6 Middle East & Africa Small Nucleic Acid Therapies Market Size Growth (2019-2024)
- 5 Americas
- 5.1 Americas Small Nucleic Acid Therapies Market Size by Country (2019-2024)
- 5.2 Americas Small Nucleic Acid Therapies Market Size by Type (2019-2024)
- 5.3 Americas Small Nucleic Acid Therapies Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Small Nucleic Acid Therapies Market Size by Region (2019-2024)
- 6.2 APAC Small Nucleic Acid Therapies Market Size by Type (2019-2024)
- 6.3 APAC Small Nucleic Acid Therapies Market Size by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Small Nucleic Acid Therapies Market Size by Country (2019-2024)
- 7.2 Europe Small Nucleic Acid Therapies Market Size by Type (2019-2024)
- 7.3 Europe Small Nucleic Acid Therapies Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Small Nucleic Acid Therapies by Region (2019-2024)
- 8.2 Middle East & Africa Small Nucleic Acid Therapies Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Small Nucleic Acid Therapies Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Small Nucleic Acid Therapies Market Forecast
- 10.1 Global Small Nucleic Acid Therapies Forecast by Region (2025-2030)
- 10.1.1 Global Small Nucleic Acid Therapies Forecast by Region (2025-2030)
- 10.1.2 Americas Small Nucleic Acid Therapies Forecast
- 10.1.3 APAC Small Nucleic Acid Therapies Forecast
- 10.1.4 Europe Small Nucleic Acid Therapies Forecast
- 10.1.5 Middle East & Africa Small Nucleic Acid Therapies Forecast
- 10.2 Americas Small Nucleic Acid Therapies Forecast by Country (2025-2030)
- 10.2.1 United States Market Small Nucleic Acid Therapies Forecast
- 10.2.2 Canada Market Small Nucleic Acid Therapies Forecast
- 10.2.3 Mexico Market Small Nucleic Acid Therapies Forecast
- 10.2.4 Brazil Market Small Nucleic Acid Therapies Forecast
- 10.3 APAC Small Nucleic Acid Therapies Forecast by Region (2025-2030)
- 10.3.1 China Small Nucleic Acid Therapies Market Forecast
- 10.3.2 Japan Market Small Nucleic Acid Therapies Forecast
- 10.3.3 Korea Market Small Nucleic Acid Therapies Forecast
- 10.3.4 Southeast Asia Market Small Nucleic Acid Therapies Forecast
- 10.3.5 India Market Small Nucleic Acid Therapies Forecast
- 10.3.6 Australia Market Small Nucleic Acid Therapies Forecast
- 10.4 Europe Small Nucleic Acid Therapies Forecast by Country (2025-2030)
- 10.4.1 Germany Market Small Nucleic Acid Therapies Forecast
- 10.4.2 France Market Small Nucleic Acid Therapies Forecast
- 10.4.3 UK Market Small Nucleic Acid Therapies Forecast
- 10.4.4 Italy Market Small Nucleic Acid Therapies Forecast
- 10.4.5 Russia Market Small Nucleic Acid Therapies Forecast
- 10.5 Middle East & Africa Small Nucleic Acid Therapies Forecast by Region (2025-2030)
- 10.5.1 Egypt Market Small Nucleic Acid Therapies Forecast
- 10.5.2 South Africa Market Small Nucleic Acid Therapies Forecast
- 10.5.3 Israel Market Small Nucleic Acid Therapies Forecast
- 10.5.4 Turkey Market Small Nucleic Acid Therapies Forecast
- 10.6 Global Small Nucleic Acid Therapies Forecast by Type (2025-2030)
- 10.7 Global Small Nucleic Acid Therapies Forecast by Application (2025-2030)
- 10.7.1 GCC Countries Market Small Nucleic Acid Therapies Forecast
- 11 Key Players Analysis
- 11.1 Sarepta Therapeutics
- 11.1.1 Sarepta Therapeutics Company Information
- 11.1.2 Sarepta Therapeutics Small Nucleic Acid Therapies Product Offered
- 11.1.3 Sarepta Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.1.4 Sarepta Therapeutics Main Business Overview
- 11.1.5 Sarepta Therapeutics Latest Developments
- 11.2 Ionis Pharmaceuticals
- 11.2.1 Ionis Pharmaceuticals Company Information
- 11.2.2 Ionis Pharmaceuticals Small Nucleic Acid Therapies Product Offered
- 11.2.3 Ionis Pharmaceuticals Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Ionis Pharmaceuticals Main Business Overview
- 11.2.5 Ionis Pharmaceuticals Latest Developments
- 11.3 Alnylam
- 11.3.1 Alnylam Company Information
- 11.3.2 Alnylam Small Nucleic Acid Therapies Product Offered
- 11.3.3 Alnylam Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 Alnylam Main Business Overview
- 11.3.5 Alnylam Latest Developments
- 11.4 Biogen
- 11.4.1 Biogen Company Information
- 11.4.2 Biogen Small Nucleic Acid Therapies Product Offered
- 11.4.3 Biogen Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Biogen Main Business Overview
- 11.4.5 Biogen Latest Developments
- 11.5 Nippon Shinyaku
- 11.5.1 Nippon Shinyaku Company Information
- 11.5.2 Nippon Shinyaku Small Nucleic Acid Therapies Product Offered
- 11.5.3 Nippon Shinyaku Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 Nippon Shinyaku Main Business Overview
- 11.5.5 Nippon Shinyaku Latest Developments
- 11.6 Sobi
- 11.6.1 Sobi Company Information
- 11.6.2 Sobi Small Nucleic Acid Therapies Product Offered
- 11.6.3 Sobi Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Sobi Main Business Overview
- 11.6.5 Sobi Latest Developments
- 11.7 Novartis
- 11.7.1 Novartis Company Information
- 11.7.2 Novartis Small Nucleic Acid Therapies Product Offered
- 11.7.3 Novartis Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 Novartis Main Business Overview
- 11.7.5 Novartis Latest Developments
- 11.8 BioNTech
- 11.8.1 BioNTech Company Information
- 11.8.2 BioNTech Small Nucleic Acid Therapies Product Offered
- 11.8.3 BioNTech Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 BioNTech Main Business Overview
- 11.8.5 BioNTech Latest Developments
- 11.9 Pfizer
- 11.9.1 Pfizer Company Information
- 11.9.2 Pfizer Small Nucleic Acid Therapies Product Offered
- 11.9.3 Pfizer Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 Pfizer Main Business Overview
- 11.9.5 Pfizer Latest Developments
- 11.10 Moderna Therapeutics
- 11.10.1 Moderna Therapeutics Company Information
- 11.10.2 Moderna Therapeutics Small Nucleic Acid Therapies Product Offered
- 11.10.3 Moderna Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Moderna Therapeutics Main Business Overview
- 11.10.5 Moderna Therapeutics Latest Developments
- 11.11 Jazz Pharmaceuticals
- 11.11.1 Jazz Pharmaceuticals Company Information
- 11.11.2 Jazz Pharmaceuticals Small Nucleic Acid Therapies Product Offered
- 11.11.3 Jazz Pharmaceuticals Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.11.4 Jazz Pharmaceuticals Main Business Overview
- 11.11.5 Jazz Pharmaceuticals Latest Developments
- 11.12 CureVac
- 11.12.1 CureVac Company Information
- 11.12.2 CureVac Small Nucleic Acid Therapies Product Offered
- 11.12.3 CureVac Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.12.4 CureVac Main Business Overview
- 11.12.5 CureVac Latest Developments
- 11.13 Regulus Therapeutics
- 11.13.1 Regulus Therapeutics Company Information
- 11.13.2 Regulus Therapeutics Small Nucleic Acid Therapies Product Offered
- 11.13.3 Regulus Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.13.4 Regulus Therapeutics Main Business Overview
- 11.13.5 Regulus Therapeutics Latest Developments
- 11.14 ProQR
- 11.14.1 ProQR Company Information
- 11.14.2 ProQR Small Nucleic Acid Therapies Product Offered
- 11.14.3 ProQR Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.14.4 ProQR Main Business Overview
- 11.14.5 ProQR Latest Developments
- 11.15 Secarna
- 11.15.1 Secarna Company Information
- 11.15.2 Secarna Small Nucleic Acid Therapies Product Offered
- 11.15.3 Secarna Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.15.4 Secarna Main Business Overview
- 11.15.5 Secarna Latest Developments
- 11.16 MiNA Therapeutics
- 11.16.1 MiNA Therapeutics Company Information
- 11.16.2 MiNA Therapeutics Small Nucleic Acid Therapies Product Offered
- 11.16.3 MiNA Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.16.4 MiNA Therapeutics Main Business Overview
- 11.16.5 MiNA Therapeutics Latest Developments
- 11.17 Sylentis
- 11.17.1 Sylentis Company Information
- 11.17.2 Sylentis Small Nucleic Acid Therapies Product Offered
- 11.17.3 Sylentis Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.17.4 Sylentis Main Business Overview
- 11.17.5 Sylentis Latest Developments
- 11.18 Arrowhead
- 11.18.1 Arrowhead Company Information
- 11.18.2 Arrowhead Small Nucleic Acid Therapies Product Offered
- 11.18.3 Arrowhead Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.18.4 Arrowhead Main Business Overview
- 11.18.5 Arrowhead Latest Developments
- 11.19 Silence Therapeutics
- 11.19.1 Silence Therapeutics Company Information
- 11.19.2 Silence Therapeutics Small Nucleic Acid Therapies Product Offered
- 11.19.3 Silence Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.19.4 Silence Therapeutics Main Business Overview
- 11.19.5 Silence Therapeutics Latest Developments
- 11.20 Dicerna
- 11.20.1 Dicerna Company Information
- 11.20.2 Dicerna Small Nucleic Acid Therapies Product Offered
- 11.20.3 Dicerna Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2019-2024)
- 11.20.4 Dicerna Main Business Overview
- 11.20.5 Dicerna Latest Developments
- 12 Research Findings and Conclusion
List of Tables
Table 1. Small Nucleic Acid Therapies Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Small Nucleic Acid Therapies Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Small Nucleic Acid Therapies Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Table 9. Small Nucleic Acid Therapies Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Table 12. Global Small Nucleic Acid Therapies Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Small Nucleic Acid Therapies Revenue Market Share by Player (2019-2024)
Table 14. Small Nucleic Acid Therapies Key Players Head office and Products Offered
Table 15. Small Nucleic Acid Therapies Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Small Nucleic Acid Therapies Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Table 20. Global Small Nucleic Acid Therapies Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Small Nucleic Acid Therapies Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Small Nucleic Acid Therapies Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Small Nucleic Acid Therapies Market Size Market Share by Country (2019-2024)
Table 24. Americas Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Table 26. Americas Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Table 28. APAC Small Nucleic Acid Therapies Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Table 30. APAC Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Small Nucleic Acid Therapies Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Small Nucleic Acid Therapies Market Size Market Share by Country (2019-2024)
Table 34. Europe Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Small Nucleic Acid Therapies Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Small Nucleic Acid Therapies
Table 40. Key Market Challenges & Risks of Small Nucleic Acid Therapies
Table 41. Key Industry Trends of Small Nucleic Acid Therapies
Table 42. Global Small Nucleic Acid Therapies Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Small Nucleic Acid Therapies Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Small Nucleic Acid Therapies Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Small Nucleic Acid Therapies Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 47. Sarepta Therapeutics Small Nucleic Acid Therapies Product Offered
Table 48. Sarepta Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Small Nucleic Acid Therapies Product Offered
Table 53. Ionis Pharmaceuticals Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 57. Alnylam Small Nucleic Acid Therapies Product Offered
Table 58. Alnylam Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 62. Biogen Small Nucleic Acid Therapies Product Offered
Table 63. Biogen Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 67. Nippon Shinyaku Small Nucleic Acid Therapies Product Offered
Table 68. Nippon Shinyaku Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 72. Sobi Small Nucleic Acid Therapies Product Offered
Table 73. Sobi Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 77. Novartis Small Nucleic Acid Therapies Product Offered
Table 78. Novartis Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 82. BioNTech Small Nucleic Acid Therapies Product Offered
Table 83. BioNTech Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 87. Pfizer Small Nucleic Acid Therapies Product Offered
Table 88. Pfizer Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 92. Moderna Therapeutics Small Nucleic Acid Therapies Product Offered
Table 93. Moderna Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Small Nucleic Acid Therapies Product Offered
Table 98. Jazz Pharmaceuticals Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 102. CureVac Small Nucleic Acid Therapies Product Offered
Table 103. CureVac Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 107. Regulus Therapeutics Small Nucleic Acid Therapies Product Offered
Table 108. Regulus Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 112. ProQR Small Nucleic Acid Therapies Product Offered
Table 113. ProQR Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 117. Secarna Small Nucleic Acid Therapies Product Offered
Table 118. Secarna Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 122. MiNA Therapeutics Small Nucleic Acid Therapies Product Offered
Table 123. MiNA Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 127. Sylentis Small Nucleic Acid Therapies Product Offered
Table 128. Sylentis Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 132. Arrowhead Small Nucleic Acid Therapies Product Offered
Table 133. Arrowhead Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 137. Silence Therapeutics Small Nucleic Acid Therapies Product Offered
Table 138. Silence Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 142. Dicerna Small Nucleic Acid Therapies Product Offered
Table 143. Dicerna Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
Table 1. Small Nucleic Acid Therapies Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Small Nucleic Acid Therapies Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Small Nucleic Acid Therapies Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Table 9. Small Nucleic Acid Therapies Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Table 12. Global Small Nucleic Acid Therapies Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Small Nucleic Acid Therapies Revenue Market Share by Player (2019-2024)
Table 14. Small Nucleic Acid Therapies Key Players Head office and Products Offered
Table 15. Small Nucleic Acid Therapies Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Small Nucleic Acid Therapies Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Table 20. Global Small Nucleic Acid Therapies Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Small Nucleic Acid Therapies Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Small Nucleic Acid Therapies Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Small Nucleic Acid Therapies Market Size Market Share by Country (2019-2024)
Table 24. Americas Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Table 26. Americas Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Table 28. APAC Small Nucleic Acid Therapies Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Table 30. APAC Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Small Nucleic Acid Therapies Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Small Nucleic Acid Therapies Market Size Market Share by Country (2019-2024)
Table 34. Europe Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Small Nucleic Acid Therapies Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Small Nucleic Acid Therapies Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Small Nucleic Acid Therapies Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Small Nucleic Acid Therapies
Table 40. Key Market Challenges & Risks of Small Nucleic Acid Therapies
Table 41. Key Industry Trends of Small Nucleic Acid Therapies
Table 42. Global Small Nucleic Acid Therapies Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Small Nucleic Acid Therapies Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Small Nucleic Acid Therapies Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Small Nucleic Acid Therapies Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 47. Sarepta Therapeutics Small Nucleic Acid Therapies Product Offered
Table 48. Sarepta Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Small Nucleic Acid Therapies Product Offered
Table 53. Ionis Pharmaceuticals Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 57. Alnylam Small Nucleic Acid Therapies Product Offered
Table 58. Alnylam Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 62. Biogen Small Nucleic Acid Therapies Product Offered
Table 63. Biogen Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 67. Nippon Shinyaku Small Nucleic Acid Therapies Product Offered
Table 68. Nippon Shinyaku Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 72. Sobi Small Nucleic Acid Therapies Product Offered
Table 73. Sobi Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 77. Novartis Small Nucleic Acid Therapies Product Offered
Table 78. Novartis Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 82. BioNTech Small Nucleic Acid Therapies Product Offered
Table 83. BioNTech Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 87. Pfizer Small Nucleic Acid Therapies Product Offered
Table 88. Pfizer Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 92. Moderna Therapeutics Small Nucleic Acid Therapies Product Offered
Table 93. Moderna Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Small Nucleic Acid Therapies Product Offered
Table 98. Jazz Pharmaceuticals Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 102. CureVac Small Nucleic Acid Therapies Product Offered
Table 103. CureVac Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 107. Regulus Therapeutics Small Nucleic Acid Therapies Product Offered
Table 108. Regulus Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 112. ProQR Small Nucleic Acid Therapies Product Offered
Table 113. ProQR Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 117. Secarna Small Nucleic Acid Therapies Product Offered
Table 118. Secarna Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 122. MiNA Therapeutics Small Nucleic Acid Therapies Product Offered
Table 123. MiNA Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 127. Sylentis Small Nucleic Acid Therapies Product Offered
Table 128. Sylentis Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 132. Arrowhead Small Nucleic Acid Therapies Product Offered
Table 133. Arrowhead Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 137. Silence Therapeutics Small Nucleic Acid Therapies Product Offered
Table 138. Silence Therapeutics Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Small Nucleic Acid Therapies Area Served and Its Competitors
Table 142. Dicerna Small Nucleic Acid Therapies Product Offered
Table 143. Dicerna Small Nucleic Acid Therapies Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
List of Figures
Figure 1. Small Nucleic Acid Therapies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Small Nucleic Acid Therapies Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Small Nucleic Acid Therapies Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Small Nucleic Acid Therapies Sales Market Share by Country/Region (2023)
Figure 8. Small Nucleic Acid Therapies Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Small Nucleic Acid Therapies Market Size Market Share by Type in 2023
Figure 10. Small Nucleic Acid Therapies in Neuromuscular Diseases
Figure 11. Global Small Nucleic Acid Therapies Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Small Nucleic Acid Therapies in hATTR
Figure 13. Global Small Nucleic Acid Therapies Market: hATTR (2019-2024) & ($ millions)
Figure 14. Small Nucleic Acid Therapies in COVID-19
Figure 15. Global Small Nucleic Acid Therapies Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Small Nucleic Acid Therapies in Other
Figure 17. Global Small Nucleic Acid Therapies Market: Other (2019-2024) & ($ millions)
Figure 18. Global Small Nucleic Acid Therapies Market Size Market Share by Application in 2023
Figure 19. Global Small Nucleic Acid Therapies Revenue Market Share by Player in 2023
Figure 20. Global Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Figure 21. Americas Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 22. APAC Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 23. Europe Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 25. Americas Small Nucleic Acid Therapies Value Market Share by Country in 2023
Figure 26. United States Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Small Nucleic Acid Therapies Market Size Market Share by Region in 2023
Figure 31. APAC Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Figure 32. APAC Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Figure 33. China Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 37. India Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Small Nucleic Acid Therapies Market Size Market Share by Country in 2023
Figure 40. Europe Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Figure 41. Europe Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Figure 42. Germany Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 43. France Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 56. APAC Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 57. Europe Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 59. United States Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 60. Canada Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 61. Mexico Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 62. Brazil Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 63. China Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 64. Japan Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 65. Korea Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 67. India Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 68. Australia Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 69. Germany Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 70. France Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 71. UK Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 72. Italy Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 73. Russia Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 74. Egypt Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 75. South Africa Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 76. Israel Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 77. Turkey Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 79. Global Small Nucleic Acid Therapies Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Small Nucleic Acid Therapies Market Size Market Share Forecast by Application (2025-2030)
"
Figure 1. Small Nucleic Acid Therapies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Small Nucleic Acid Therapies Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Small Nucleic Acid Therapies Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Small Nucleic Acid Therapies Sales Market Share by Country/Region (2023)
Figure 8. Small Nucleic Acid Therapies Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Small Nucleic Acid Therapies Market Size Market Share by Type in 2023
Figure 10. Small Nucleic Acid Therapies in Neuromuscular Diseases
Figure 11. Global Small Nucleic Acid Therapies Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Small Nucleic Acid Therapies in hATTR
Figure 13. Global Small Nucleic Acid Therapies Market: hATTR (2019-2024) & ($ millions)
Figure 14. Small Nucleic Acid Therapies in COVID-19
Figure 15. Global Small Nucleic Acid Therapies Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Small Nucleic Acid Therapies in Other
Figure 17. Global Small Nucleic Acid Therapies Market: Other (2019-2024) & ($ millions)
Figure 18. Global Small Nucleic Acid Therapies Market Size Market Share by Application in 2023
Figure 19. Global Small Nucleic Acid Therapies Revenue Market Share by Player in 2023
Figure 20. Global Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Figure 21. Americas Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 22. APAC Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 23. Europe Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Small Nucleic Acid Therapies Market Size 2019-2024 ($ millions)
Figure 25. Americas Small Nucleic Acid Therapies Value Market Share by Country in 2023
Figure 26. United States Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Small Nucleic Acid Therapies Market Size Market Share by Region in 2023
Figure 31. APAC Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Figure 32. APAC Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Figure 33. China Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 37. India Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Small Nucleic Acid Therapies Market Size Market Share by Country in 2023
Figure 40. Europe Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Figure 41. Europe Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Figure 42. Germany Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 43. France Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Small Nucleic Acid Therapies Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Small Nucleic Acid Therapies Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Small Nucleic Acid Therapies Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Small Nucleic Acid Therapies Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 56. APAC Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 57. Europe Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 59. United States Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 60. Canada Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 61. Mexico Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 62. Brazil Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 63. China Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 64. Japan Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 65. Korea Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 67. India Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 68. Australia Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 69. Germany Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 70. France Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 71. UK Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 72. Italy Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 73. Russia Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 74. Egypt Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 75. South Africa Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 76. Israel Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 77. Turkey Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Small Nucleic Acid Therapies Market Size 2025-2030 ($ millions)
Figure 79. Global Small Nucleic Acid Therapies Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Small Nucleic Acid Therapies Market Size Market Share Forecast by Application (2025-2030)
"
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. Read More
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. Read More
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. Read More
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization.png "Nikita Jabrela")
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (03 May, 2025)
- Notify To Team (03 May, 2025)
- Report updation (04 May, 2025)
- Report Quality Check (04 May, 2025)
- Report Dispatch (05 May, 2025)
- Hard Copy
Recently Viewed Products
Global Small Nucleic Acid Therapies Market Outlook , 2030
We are friendly and approachable, give us a call.